First Time in Human Study of Long Acting VH4524184 Formulations
Status:
RECRUITING
Trial end date:
2028-01-21
Target enrollment:
Participant gender:
Summary
The purpose of this study is to identify 1 or more doses of parenterally administered VH4524184 that are safe, well tolerated and yield a PK drug exposure profile necessary to deliver a long-acting antiretroviral therapy for the treatment of HIV-1 infection.